Product nameAnti-EMAP II/AIMP1 antibody [546-2]
See all EMAP II/AIMP1 primary antibodies
DescriptionMouse monoclonal [546-2] to EMAP II/AIMP1
Tested applicationsSuitable for: IHC-Fr, IHC-P, ELISA, WBmore details
Species reactivityReacts with: Rat, Human
Recombinant full length protein corresponding to Human EMAP II/AIMP1.
This product was previously labelled as EMAP II
Storage instructionsShipped at 4°C. Upon delivery aliquot. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.09% Sodium azide
Concentration information loading...
PurityProtein G purified
Our Abpromise guarantee covers the use of ab15693 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/40. Perform heat mediated antigen retrieval via the microwave method before commencing with IHC staining protocol.|
|ELISA||Use at an assay dependent dilution.|
|WB||Use at an assay dependent dilution. Predicted molecular weight: 34 kDa.|
FunctionNon-catalytic component of the multisynthase complex. Stimulates the catalytic activity of cytoplasmic arginyl-tRNA synthase. Binds tRNA. Possesses inflammatory cytokine activity. Negatively regulates TGF-beta signaling through stabilization of SMURF2 by binding to SMURF2 and inhibiting its SMAD7-mediated degradation. Involved in glucose homeostasis through induction of glucagon secretion at low glucose levels. Promotes dermal fibroblast proliferation and wound repair. Regulates KDELR1-mediated retention of HSP90B1/gp96 in the endoplasmic reticulum. Plays a role in angiogenesis by inducing endothelial cell migration at low concentrations and endothelian cell apoptosis at high concentrations. Induces maturation of dendritic cells and monocyte cell adhesion. Modulates endothelial cell responses by degrading HIF-1A through interaction with PSMA7.
Involvement in diseaseDefects in AIMP1 are the cause of leukodystrophy hypomyelinating type 3 (HLD3) [MIM:260600]. A severe autosomal recessive hypomyelinating leukodystrophy characterized by early infantile onset of global developmental delay, lack of development, lack of speech acquisition, and peripheral spasticity associated with decreased myelination in the central nervous system.
Sequence similaritiesContains 1 tRNA-binding domain.
modificationsCleaved by caspase-7 in response to apoptosis to produce EMAP-II.
Cellular localizationNucleus. Cytoplasm > cytosol. Cytoplasmic vesicle > secretory vesicle. Secreted. Endoplasmic reticulum. Golgi apparatus. Enriched in secretory vesicles of pancreatic alpha cells and secreted from the pancreas in response to low glucose levels (By similarity). Also secreted in response to hypoxia and both apoptotic and necrotic cell death.
- Information by UniProt
- AIMP 1 antibody
- Aimp1 antibody
- AIMP1/p43 antibody
Lanes 1-4 & 6-9 : Anti-EMAP II/AIMP1 antibody [546-2] (ab15693) at 1/1000 dilution
Lane 1 : HeLa Cytoplasmic Extract (0.625ug)
Lane 2 : HeLa Cytoplasmic Extract (1.25ug)
Lane 3 : HeLa Cytoplasmic Extract (2.5ug)
Lane 4 : HeLa Cytoplasmic Extract (5ug)
Lanes 5 & 10 : High Range Rainbow MWMs
Lane 6 : HeLa Nuclear Extract (0.625ug)
Lane 7 : HeLa Nuclear Extract (1.25ug)
Lane 8 : HeLa Nuclear Extract (2.5ug)
Lane 9 : HeLa Nuclear Extract (5ug)
Lanes 1-4 & 6-9 : HRP conjugated Sheep anti-mouse IgG
Predicted band size: 34 kDa
Observed band size: 43 kDa why is the actual band size different from the predicted?
Additional bands at: 50 kDa (possible non-specific binding), 66 kDa (possible non-specific binding), 80 kDa (possible non-specific binding)
Samples were run on a 4-12% polyacrylamide gradient gel (SDS, Bis-Tris). Blocking and secondary antibody incubations were at room temperature. Primary antibody incubation was at 4°C.Primary and secondary antibodies were diluted in TBST containing 5% milk.
The predominant band observed was 43 kDa, consistent with the expected mobility of pro-EmapII/p43. The 21kDa "cleaved" form, EmapII, was not observed most likely because the cells were not treated to induce cleavage of pro-EmapII to release EmapII. The identity of the 50kDa "nonspecific" band is not known, but it does not appear as prominent when a different EmapII antibody (ab10605) is used.
This product has been referenced in:
- Pechenino AS et al. Impact of aging vs. estrogen loss on cardiac gene expression: estrogen replacement and inflammation. Physiol Genomics 43:1065-73 (2011). WB ; Rat . Read more (PubMed: 21750230) »
- Marik C et al. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130:2800-15 (2007). ICC/IF . Read more (PubMed: 17956913) »